In the treatment of non-metastatic insulinomas, which of the following statements regarding octreotide and/or lanreotide are correct?

Randomized data showed an improvement in progression free survival with lanreotide vs. placebo. 33% (3 votes)
In the absence of insulinoma somatostatin receptors, octreotide or lanreotide can profoundly worsen hypoglycemia. 44% (4 votes)
Octreotide is more easily administered than lanreotide. 11% (1 vote)
Lanreotide is significantly more effective than octreotide in decreasing excess tumor hormone production. 11% (1 vote)

Total Votes: 9

Give others the chance to vote.